News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Repros Therapeutics Inc. (RPRX) Initiates Two Head To Head Studies Of Androxal® Versus The Leading Topical Testosterone Gel



1/8/2014 9:08:16 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

THE WOODLANDS, Texas, Jan. 8, 2014 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced it has initiated two clinical studies comparing Androxal to the leading US testosterone replacement therapy. Investigational Review Board approval has already been obtained for several of the study sites and an investigator meeting and shipment of drug is scheduled for next week. Several sites have begun pre-screening subjects. The FDA has previously indicated that head to head studies could be conducted against approved testosterone products to establish claims for labeling purposes with the proviso that Androxal must show superiority to the testosterone product for any specific claims to be made.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES